David A. Horst

The paper identifies tumor-reactive TCRs using T/N ratios and validates them with single-cell and spatial data, showing their tumor association and effector phenotype.

This study shows that combining AXL inhibition with RAS or ERK inhibitors enhances efficacy in KRAS-mutant cancers by overcoming resistance mechanisms.

This paper uses spatial multi-omics to identify immunosuppressive interactions between AML, macrophages, and T cells in bone marrow, highlighting the Galectin-9 - CD44/TIM-3 axis as a therapeutic target.

The paper identifies two neuroendocrine cell states in large-cell pancreatic neuroendocrine carcinoma using single-nucleus transcriptomics, revealing an aberrant brain-type neuronal program and a stress-responsive state.

The paper quantitatively analyzes morphological heterogeneity in colorectal adenocarcinoma, finding that specific morphotypes correlate with clinical outcomes.

The paper identifies CACNA2D2 as a super-enhancer-driven target of EWSR1::WT1 and demonstrates its utility as a diagnostic biomarker for DSRCT.

The paper develops CCISM to distinguish cancer cells from normal epithelial cells in single-cell data, identifying a novel stem-like cell state in the colorectal cancer microenvironment.

The paper investigates SARS-CoV-2 entry into the CNS via the olfactory mucosa in COVID-19 patients and demonstrates neurotropism and cerebral thromboembolism.